MedLumics has raised another €18 million (around $22 million) to fund clinical trials of its optically-guided imaging system used to guide a surgical procedure for atrial fibrillation (AF) – a serious ...

MADRID--(BUSINESS WIRE)--MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, debuted its NITID TM skin imaging system at the 23 rd Annual ...

MADRID--(BUSINESS WIRE)--MedLumics, a medical device company developing fiber optically guided platform technologies for the treatment, initially, of Atrial fibrillation (AF), announced today 10 ...

MADRID, Feb. 10, 2021 /PRNewswire/ -- MedLumics, a privately held medical device company developing AblaView, the first optically-guided real-time ablation catheter system for the treatment of Atrial ...

MADRID, MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the completion of a successful single-case pre-clinical feasibility ...

1) Initial heart wall contact confirmation: ability to differentiate between ablated and un-ablated tissue, eliminating gaps in treatment lines and avoiding non-contact and excessive ablations. 2) ...

"This is a key milestone in validating a definitive Atrial Fibrillation (AF) ablation system using PFA and Optical Coherence Reflectometry (OCR) to monitor and confirm the success of ablation under ...

MedLumics will use the money to develop an optically guided radiofrequency ablation catheter () MedLumics has raised $37 million to run clinical trials of its atrial fibrillation device. The Series B ...

MedLumics' AblaView system uses optical coherence tomography to directly observe the creation of ablation lesions in the cardiac muscle. (Pixabay/PublicDomainPictures) MedLumics has raised €18 million ...

MADRID — “This is a key milestone in validating a definitive Atrial Fibrillation (AF) ablation system using PFA and Optical Coherence Reflectometry (OCR) to monitor and confirm the success of ablation ...